Literature DB >> 25285303

Alzheimer's Disease in Down Syndrome.

Elizabeth Head1, David Powell2, Brian T Gold3, Frederick A Schmitt4.   

Abstract

A key challenge to adults with Down syndrome (DS) as they age is an increased risk for cognitive decline, dementia, and Alzheimer disease (AD). In DS persons ranging from 40-49 years of age, 5.7-55% may be clinically demented and between 50-59 years, dementia prevalence ranges from 4-55% (reviewed in [1]). Despite the wide ranges reported for dementia prevalence, a consistent feature of aging in DS is the progressive accumulation of AD brain pathologies. By the age of 40 years, virtually all have sufficient senile plaques and neurofibrillary tangles for a neuropathological diagnosis of AD [2]. Thus, there is dissociation between the age of onset of AD neuropathology (40 years) and increasing signs of clinical dementia. We discuss the hypothesis that frontal impairments are a critical factor affecting cognitive function and are associated with white matter (WM) and AD neuropathology. While these may be an early sign of conversion to dementia, we also review several other clinical comorbidities that may also contribute to dementia onset.

Entities:  

Keywords:  Trisomy 21; beta-amyloid; dementia; neurofibrillary tangles; oxidative damage

Year:  2012        PMID: 25285303      PMCID: PMC4184282     

Source DB:  PubMed          Journal:  Eur J Neurodegener Dis        ISSN: 2279-5855


  98 in total

Review 1.  Genetic and host factors for dementia in Down's syndrome.

Authors:  Nicole Schupf; Gertrude H Sergievsky
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

Review 2.  Diffusion tensor imaging and aging - a review.

Authors:  Michael Moseley
Journal:  NMR Biomed       Date:  2002 Nov-Dec       Impact factor: 4.044

Review 3.  Down syndrome and beta-amyloid deposition.

Authors:  Elizabeth Head; Ira T Lott
Journal:  Curr Opin Neurol       Date:  2004-04       Impact factor: 5.710

4.  Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome.

Authors:  Anne M Cataldo; Suzana Petanceska; Nicole B Terio; Corrinne M Peterhoff; Robert Durham; Marc Mercken; Pankaj D Mehta; Joseph Buxbaum; Vahram Haroutunian; Ralph A Nixon
Journal:  Neurobiol Aging       Date:  2004 Nov-Dec       Impact factor: 4.673

5.  Precocious aging and dementia in patients with Down's syndrome.

Authors:  K Wisniewski; J Howe; D G Williams; H M Wisniewski
Journal:  Biol Psychiatry       Date:  1978-10       Impact factor: 13.382

6.  The four ages of Down syndrome.

Authors:  Alan H Bittles; Carol Bower; Rafat Hussain; Emma J Glasson
Journal:  Eur J Public Health       Date:  2006-07-19       Impact factor: 3.367

7.  Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.

Authors:  S E Stoltzner; T J Grenfell; C Mori; K E Wisniewski; T M Wisniewski; D J Selkoe; C A Lemere
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

8.  Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease.

Authors:  B Rumble; R Retallack; C Hilbich; G Simms; G Multhaup; R Martins; A Hockey; P Montgomery; K Beyreuther; C L Masters
Journal:  N Engl J Med       Date:  1989-06-01       Impact factor: 91.245

Review 9.  Epidemiology of Alzheimer disease.

Authors:  Christiane Reitz; Carol Brayne; Richard Mayeux
Journal:  Nat Rev Neurol       Date:  2011-02-08       Impact factor: 42.937

10.  Upregulation of phosphorylated alphaB-crystallin in the brain of children and young adults with Down syndrome.

Authors:  Sonia Palminiello; Katarzyna Jarząbek; Kulbir Kaur; Marius Walus; Ausma Rabe; Giorgio Albertini; Adam A Golabek; Elizabeth Kida
Journal:  Brain Res       Date:  2009-03-09       Impact factor: 3.252

View more
  53 in total

Review 1.  Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Authors:  Donna M Wilcock; Frederick A Schmitt; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2015-11-26

Review 2.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

Review 3.  Synthetic combinations of missense polymorphic genetic changes underlying Down syndrome susceptibility.

Authors:  Rebecca A Jackson; Mai Linh Nguyen; Angela N Barrett; Yuan Yee Tan; Mahesh A Choolani; Ee Sin Chen
Journal:  Cell Mol Life Sci       Date:  2016-05-31       Impact factor: 9.261

Review 4.  Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.

Authors:  Eric D Hamlett; Heather A Boger; Aurélie Ledreux; Christy M Kelley; Elliott J Mufson; Maria F Falangola; David N Guilfoyle; Ralph A Nixon; David Patterson; Nathan Duval; Ann-Charlotte E Granholm
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 5.  Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Authors:  Eugenio Barone; Andrea Arena; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2017-07-10       Impact factor: 7.376

6.  Synaptic actin stabilization protein loss in Down syndrome and Alzheimer disease.

Authors:  Julie C Lauterborn; Conor D Cox; See Wing Chan; Peter W Vanderklish; Gary Lynch; Christine M Gall
Journal:  Brain Pathol       Date:  2019-09-08       Impact factor: 6.508

Review 7.  The basis of cellular and regional vulnerability in Alzheimer's disease.

Authors:  Dunja Mrdjen; Edward J Fox; Syed A Bukhari; Kathleen S Montine; Sean C Bendall; Thomas J Montine
Journal:  Acta Neuropathol       Date:  2019-08-07       Impact factor: 17.088

8.  Automated Detection of Alzheimer's Disease Using Brain MRI Images- A Study with Various Feature Extraction Techniques.

Authors:  U Rajendra Acharya; Steven Lawrence Fernandes; Joel En WeiKoh; Edward J Ciaccio; Mohd Kamil Mohd Fabell; U John Tanik; V Rajinikanth; Chai Hong Yeong
Journal:  J Med Syst       Date:  2019-08-09       Impact factor: 4.460

Review 9.  Down syndrome, beta-amyloid and neuroimaging.

Authors:  Elizabeth Head; Alex M Helman; David Powell; Frederick A Schmitt
Journal:  Free Radic Biol Med       Date:  2017-09-19       Impact factor: 7.376

Review 10.  Gait dyspraxia as a clinical marker of cognitive decline in Down syndrome: A review of theory and proposed mechanisms.

Authors:  Amelia J Anderson-Mooney; Frederick A Schmitt; Elizabeth Head; Ira T Lott; Kenneth M Heilman
Journal:  Brain Cogn       Date:  2016-02-27       Impact factor: 2.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.